Overcoming the boundaries of gene editing by unlocking the full potential of recombinases.
About Us
Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying this novel technology to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.
Leadership
The Seamless Therapeutics leadership team is comprised of passionate industry leaders with decades of proven expertise. They share a common vision to transform the gene-editing landscape.
Albert Seymour, PhD
President & CEO
Managing Director, GmbH
Deborah Kinch, PhD
Chief Development Officer
Felix Lansing, PhD
Scientific Co-Founder & CTO
Anne-Kristin Heninger, PhD
Co-Founder & Head of Operations Dresden
Managing Director, GmbH
Board of Directors & Advisors
Investors
Seamless Therapeutics is supported by leading life-science investors.
News & Press Releases
Dresden, Germany, and Greater Boston, MA, April 23, 2024
Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform
READ MORE
Careers
We are a dynamic team pioneering a groundbreaking new gene-editing approach with a deep understanding of recombinases and their potential in repairing genes that cause serious diseases. We foster creativity, leadership, and teamwork, and empower our people to make decisions and contribute positively to our goals. We also offer a supportive environment for colleagues to learn from each other, tackle challenges together, and celebrate our achievements.
We are always looking for dedicated and visionary employees with a diverse range of talents and welcome interest from applicants hoping to join us on our mission. Please send a short cover letter and CV to jobs@seamlesstx.com.